The roles of extrachromosomal DNA in tumorigenesis and therapeutic resistance in cancer.
Extrachromosomal DNA (ecDNA) is a form of circular DNA that exists independently of chromosomes.
APA
Zhang Y, Li J, et al. (2026). The roles of extrachromosomal DNA in tumorigenesis and therapeutic resistance in cancer.. Life sciences, 389, 124223. https://doi.org/10.1016/j.lfs.2026.124223
MLA
Zhang Y, et al.. "The roles of extrachromosomal DNA in tumorigenesis and therapeutic resistance in cancer.." Life sciences, vol. 389, 2026, pp. 124223.
PMID
41587635
Abstract
Extrachromosomal DNA (ecDNA) is a form of circular DNA that exists independently of chromosomes. Predominantly observed in tumor cells, ecDNA represents a key manifestation of genomic instability in cancer. In contrast to chromosomal DNA, ecDNA has a circular structure, often includes intact or fragmented gene sequences, and exhibits high copy number variation. Recent studies have shown that oncogene amplification on ecDNA is prevalent in many cancer types. This illustrates the significance of its role in the development and progression of cancer. Furthermore, ecDNA can induce drug resistance and adversely affect patient prognosis via various mechanisms, demonstrating considerable biological and potential therapeutic significance in preclinical investigations. This review outlines the key characteristics of ecDNA, analyzes its role in carcinogenesis and drug resistance, and evaluates current detection methods, aiming to explore its potential as a therapeutic target in cancer treatment.
MeSH Terms
Humans; Neoplasms; Drug Resistance, Neoplasm; Carcinogenesis; Animals; DNA, Circular; DNA Copy Number Variations; Genomic Instability
같은 제1저자의 인용 많은 논문 (5)
- Comment on: "Interpretable machine learning model for predicting early recurrence of pancreatic cancer: integrating intratumoral and peritumoral radiomics with body composition".
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Impact of contrast-enhanced computed tomography surveillance frequency on survival outcomes in patients with stage I-III colorectal cancer: A propensity score-matched retrospective cohort study.
- Corrigendum to "TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer" [Int. Immunopharmacol. 168 (2026) 115798].
- Dietary restriction genes as modulators of breast cancer risk through metabolic pathways.